AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

AstraZeneca PLC ADR closed 13.33% below its 52-week high of $87.68, which the company achieved on August 30th.

The biopharmaceutical company develops drugs for cancer ... Alnylam by securing an EU approval for Wainzua. On Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN ...

AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

AstraZeneca. The fusion between Swedish pharmaceutical company, Astra AB, and UK-based Zeneca Group plc, was one of the largest-ever European mergers at the time. Since the mid-1890s, Swedish ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...